Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Details for Australian Patent Application No. 2004202301 (hide)

Owner Teva Pharmaceutical Industries Ltd.

Inventors Lidor-Hadas, Ramy; Aronhime, Judith; Finkelstein, Nina

Agent Shelston IP

Pub. Number AU-B-2004202301

Parent 56988

Filing date 26 May 2004

Wipo publication date 24 June 2004

Acceptance publication date 3 April 2008

International Classifications

C07F 9/38 (2006.01) Compounds containing elements of the 5th Group of the Periodic System

Event Publications

10 June 2004 Complete Application Filed

24 June 2004 Application Open to Public Inspection

  Published as AU-B-2004202301

3 April 2008 Application Accepted

  Published as AU-B-2004202301

7 August 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004202302-Apparatus and Method for Concurrent Chemical Synthesis

2004202300-Arabidopsis ARGOS, a novel gene involved in organ development